These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 21365672)

  • 21. CRM2DIM: A SAS macro for implementing the dual-agent Bayesian continual reassessment method.
    Bayar MA; Ivanova A; Le Teuff G
    Comput Methods Programs Biomed; 2019 Jul; 176():211-223. PubMed ID: 31200907
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I trial design for drug combinations with Bayesian model averaging.
    Jin IH; Huo L; Yin G; Yuan Y
    Pharm Stat; 2015; 14(2):108-19. PubMed ID: 25641851
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The continual reassessment method and its applications: a Bayesian methodology for phase I cancer clinical trials.
    Ishizuka N; Ohashi Y
    Stat Med; 2001 Sep 15-30; 20(17-18):2661-81. PubMed ID: 11523075
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multi-stage dose expansion cohort (MSDEC) design with Bayesian stopping rule.
    Wang S; Tan M
    J Biopharm Stat; 2022 Jul; 32(4):600-612. PubMed ID: 35699319
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How to design a dose-finding study using the continual reassessment method.
    Wheeler GM; Mander AP; Bedding A; Brock K; Cornelius V; Grieve AP; Jaki T; Love SB; Odondi L; Weir CJ; Yap C; Bond SJ
    BMC Med Res Methodol; 2019 Jan; 19(1):18. PubMed ID: 30658575
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A nonparametric Bayesian method for dose finding in drug combinations cancer trials.
    Razaee ZS; Cook-Wiens G; Tighiouart M
    Stat Med; 2022 Mar; 41(6):1059-1080. PubMed ID: 35075652
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The continual reassessment method: comparison of Bayesian stopping rules for dose-ranging studies.
    Zohar S; Chevret S
    Stat Med; 2001 Oct; 20(19):2827-43. PubMed ID: 11568943
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Application of the continual reassessment method to a phase I dose-finding trial in Japanese patients: East meets West.
    Morita S
    Stat Med; 2011 Jul; 30(17):2090-7. PubMed ID: 21500239
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of irrational dose assignment definitions using the continual reassessment method.
    Wages NA; Bagley E
    Clin Trials; 2019 Dec; 16(6):665-672. PubMed ID: 31547691
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adaptive prior variance calibration in the Bayesian continual reassessment method.
    Zhang J; Braun TM; Taylor JM
    Stat Med; 2013 Jun; 32(13):2221-34. PubMed ID: 22987660
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Randomized CRM: An Approach to Overcoming the Long-Memory Property of the CRM.
    Koopmeiners JS; Wey A
    J Biopharm Stat; 2017; 27(6):1028-1042. PubMed ID: 28340333
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A semi-mechanistic dose-finding design in oncology using pharmacokinetic/pharmacodynamic modeling.
    Su X; Li Y; Müller P; Hsu CW; Pan H; Do KA
    Pharm Stat; 2022 Nov; 21(6):1149-1166. PubMed ID: 35748220
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Bayesian dose-finding design incorporating toxicity data from multiple treatment cycles.
    Yin J; Qin R; Ezzalfani M; Sargent DJ; Mandrekar SJ
    Stat Med; 2017 Jan; 36(1):67-80. PubMed ID: 27633877
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Would the Recommended Dose Have Been Different Using Novel Dose-Finding Designs? Comparing Dose-Finding Designs in Published Trials.
    Silva RB; Yap C; Carvajal R; Lee SM
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250415
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modeling adverse event counts in phase I clinical trials of a cytotoxic agent.
    Muenz DG; Braun TM; Taylor JM
    Clin Trials; 2018 Aug; 15(4):386-397. PubMed ID: 29779418
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A simulation-based comparison of the traditional method, Rolling-6 design and a frequentist version of the continual reassessment method with special attention to trial duration in pediatric Phase I oncology trials.
    Onar-Thomas A; Xiong Z
    Contemp Clin Trials; 2010 May; 31(3):259-70. PubMed ID: 20298812
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel model of the continual reassessment method in Phase I trial.
    Zhang W; Lei W; Zhu X
    Sci Rep; 2023 Mar; 13(1):5047. PubMed ID: 36977709
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Bayesian adaptive design for cancer phase I trials using a flexible range of doses.
    Tighiouart M; Cook-Wiens G; Rogatko A
    J Biopharm Stat; 2018; 28(3):562-574. PubMed ID: 28858566
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Implementing and assessing Bayesian response-adaptive randomisation for backfilling in dose-finding trials.
    Pin L; Villar SS; Dehbi HM
    Contemp Clin Trials; 2024 Jul; 142():107567. PubMed ID: 38729298
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Practical model-based dose-finding in phase I clinical trials: methods based on toxicity.
    Thall PF; Lee SJ
    Int J Gynecol Cancer; 2003; 13(3):251-61. PubMed ID: 12801254
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.